OTC · CIK 0001016504
INBP INTEGRATED BIOPHARMA INC
Insider trading from SEC Form 4. Last filing Jun 20, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at INTEGRATED BIOPHARMA INC, scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 23 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2025 | Damon DeSantis director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 20, 2025 |
| Jun 18, 2025 | Eric J Friedman director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 20, 2025 |
| Jun 18, 2025 | William H. Milmoe director, owner | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 20, 2025 |
| Jun 18, 2025 | Robert Canarick director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 20, 2025 |
| May 30, 2025 | William H. Milmoe director, owner | AGrant or award Common Stock | +50,000 | $0.09 | $4,500 | 138,667 | May 30, 2025 |
| May 30, 2025 | William H. Milmoe director, owner | DDisposition to issuer Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | May 30, 2025 |
| May 21, 2025 | Robert Canarick director | AGrant or award Common Stock | +175,000 | $0.09 | $16k | 234,233 | May 22, 2025 |
| May 21, 2025 | Dina Masi Chief Financial Officer | AGrant or award Common Stock | +135,000 | $0.09 | $12k | 347,200 | May 22, 2025 |
| May 21, 2025 | Sheppard Riva Co-Chief Executive Officer | AGrant or award Common Stock | +144,445 | $0.09 | $13k | 1,473,467 | May 22, 2025 |
| May 21, 2025 | Christina Kay Co-Chief Executive Officer | AGrant or award Common Stock | +144,445 | $0.09 | $13k | 1,473,467 | May 22, 2025 |
| May 21, 2025 | Christina Kay Co-Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -144,445 | $0.00 | $0 | 0 | May 22, 2025 |
| May 21, 2025 | Sheppard Riva Co-Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -144,445 | $0.00 | $0 | 0 | May 22, 2025 |
| May 21, 2025 | Dina Masi Chief Financial Officer | DDisposition to issuer Stock Option (right to buy)derivative | -135,000 | $0.00 | $0 | 0 | May 22, 2025 |
| May 21, 2025 | Robert Canarick director | DDisposition to issuer Stock Option (Right to Buy)derivative | -175,000 | $0.00 | $0 | 0 | May 22, 2025 |
| Dec 4, 2024 | Sheppard Riva Co-Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 5, 2024 |
| Dec 4, 2024 | Christina Kay Co-Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 5, 2024 |
| Dec 4, 2024 | Dina Masi Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 5, 2024 |
| Nov 25, 2024 | Sheppard Riva Co-Chief Executive Officer | AGrant or award Common Stock | +55,555 | $0.09 | $5,000 | 1,329,022 | Nov 25, 2024 |
| Nov 25, 2024 | Dina Masi Chief Financial Officer | AGrant or award Common Stock | +65,000 | $0.09 | $5,850 | 212,200 | Nov 25, 2024 |
| Nov 25, 2024 | Christina Kay Co-Chief Executive Officer | AGrant or award Common Stock | +55,555 | $0.09 | $5,000 | 1,329,022 | Nov 25, 2024 |
| Nov 25, 2024 | Sheppard Riva Co-Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -55,555 | $0.00 | $0 | 144,445 | Nov 25, 2024 |
| Nov 25, 2024 | Dina Masi Chief Financial Officer | DDisposition to issuer Stock Option (right to buy)derivative | -65,000 | $0.00 | $0 | 135,000 | Nov 25, 2024 |
| Nov 25, 2024 | Christina Kay Co-Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -55,555 | $0.00 | $0 | 144,445 | Nov 25, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Robert Canarickdirector
- Damon DeSantisdirector
- Eric J Friedmandirector
- Christina KayCo-Chief Executive Officer
- Dina MasiChief Financial Officer
- William H. Milmoeowner, director
- Sheppard RivaCo-Chief Executive Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.